3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
92
Recurrence
11
Neoplasms, Plasma Cell
9
Lymphoma
8
Lymphoma, Mantle-Cell
6
Waldenstrom Macroglobulinemia
5
Smoldering Multiple Myeloma
4
Lymphoma, Non-Hodgkin
4
Lymphoma, Large B-Cell, Diffuse
4
Lymphoma, T-Cell, Peripheral
3
Lymphoma, B-Cell, Marginal Zone
3
Leukemia
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Mycosis Fungoides
2
Lymphoma, T-Cell, Cutaneous
2
Lymphoma, T-Cell
2
Hodgkin Disease
2
Hematologic Neoplasms
2
Sezary Syndrome
1
Salivary Gland Adenoma, Pleomorphic
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Follicular
1
Lymphoma, Extranodal NK-T-Cell
1
Lung Neoplasms
1
Leukemia, Prolymphocytic
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Interventions
Dexamethasone
16
Calcium Dobesilate
9
Melphalan
6
Lenalidomide
6
Cyclophosphamide
5
Bortezomib
5
pomalidomide
3
venetoclax
2
daratumumab
2
Thalidomide
2
Doxycycline
2
Biopsy
2
4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene
2
selinexor
1
pegfilgrastim
1
ixazomib
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carfilzomib
1
belantamab mafodotin
1
auricularum
1
Vinorelbine
1
Technetium Tc 99m Pyrophosphate
1
Technetium
1
Tacrolimus
1
Surveys and Questionnaires
1
Interleukin-2
1
In Situ Hybridization, Fluorescence
1
In Situ Hybridization
1
Hyaluronoglucosaminidase
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Amyloidosis
×
carfilzomib
×
Clear all
NCT02545907
2021-04-15
CATALYST
University College, London
Phase 1/2
Completed
10 enrolled
14 charts